Results 111 to 120 of about 238,614 (342)
مجله دانشکده پزشکی اصفهان, 2019 Background: Recombinant human interleukin-1 receptor antagonist (IL-1RA) is a protein with 153 amino acids and molecular weight of 16.83 kDa. This drug protein is known as Anakinra, and has an effective application in the treatment of rheumatoid ...
Hanieh Fardgoli +2 more
doaj +1 more source
Advanced Biology, EarlyView.The axolotl's remarkable regenerative abilities decline with age, the causes may include the numerous repetitive elements within its genome. This study uncovers how Ty3 retrotransposons and coexpression networks involving muscle and immune pathways respond to aging and regeneration, suggesting that transposons respond to physiological shifts and may ...
Samuel Ruiz‐Pérez +8 more
wiley +1 more source
Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]
, 2012 Peer reviewedPublisher ...
Walsh, Garry M.
core +2 more sources
Time‐Controlled Dual Targeting to Program Systemic and Intercellular Transfer of Therapeutic Effects
Advanced Functional Materials, EarlyView.Aspirin‐liposomes loaded onto monocytes enable inflammation‐triggered targeting and efficient hand‐over of aspirin to inflamed cells. Monocytes uptake a significant portion of aspirin‐liposomes, prolonging therapeutic action. This approach enhances anti‐inflammatory effects through intercellular transfer, demonstrating a translational strategy for ...
Seung Eun Yu +6 more
wiley +1 more source
Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. [PDF]
, 2019 The bacterium Mycobacterium tuberculosis (Mtb) causes tuberculosis and is responsible for more human mortality than any other single pathogen1. Progression to active disease occurs in only a fraction of infected individuals and is predicted by an ...
Chen, Katherine J +6 more
core
Natriuretic peptide receptors regulate cytoprotective effects in a human ex vivo 3D/bioreactor model [PDF]
, 2013 © 2013 Peake et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and ...
Achan, P +8 more
core +2 more sources
Mitoprotective effect of the receptor antagonist interleukin-1 in experimental cerebral stroke
Patologìâ, 2012 Mitoprotective activity of the receptor antagonist of interleukin-1 ( RAIL-1, 7,5 mg/kg) comparing to Thiotriazoline (50 mg/kg) was studied on the model of experimental photoinduced cerebral thrombosis in rats.
E. V. Suprun
doaj +1 more source
Advanced Functional Materials, EarlyView.This review highlights recent advances in engineering artificial antigen‐presenting cells (aAPCs) as alternatives to dendritic cells for T cell expansion. Key design principles inspired by the immunological synapse are discussed, with emphasis on strategies for polyclonal and antigen‐specific T cell expansion.
Nguyen Thi Nguyen, Yu Seok Youn
wiley +1 more source
Journal of Neuroinflammation, 2014 BackgroundInterleukin-1 (IL-1) is a key mediator of ischaemic brain injury induced by stroke and subarachnoid haemorrhage (SAH). IL-1 receptor antagonist (IL-1Ra) limits brain injury in experimental stroke and reduces plasma inflammatory mediators ...
Navneet Singh +10 more
semanticscholar +1 more source
The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis
Reumatismo, 2011 The safety profile of interleukin-1 receptor antagonist (anakinra) has been studied with randomised, placebo-controlled trials involving 2932 patients affected by rheumatoid arthritis.
L. Riente
doaj +1 more source